APLI Stock Overview
A biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Appili Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.035 |
| 52 Week High | CA$0.06 |
| 52 Week Low | CA$0.025 |
| Beta | 0.97 |
| 11 Month Change | -12.50% |
| 3 Month Change | -12.50% |
| 1 Year Change | 0% |
| 33 Year Change | -78.79% |
| 5 Year Change | -93.97% |
| Change since IPO | -95.63% |
Recent News & Updates
Shareholder Returns
| APLI | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 16.7% | -5.2% | 1.3% |
| 1Y | 0% | -23.4% | 23.1% |
Return vs Industry: APLI exceeded the Canadian Pharmaceuticals industry which returned -22.3% over the past year.
Return vs Market: APLI underperformed the Canadian Market which returned 21.7% over the past year.
Price Volatility
| APLI volatility | |
|---|---|
| APLI Average Weekly Movement | 23.4% |
| Pharmaceuticals Industry Average Movement | 12.0% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: APLI's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: APLI's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 9 | Don Cilla | appilitherapeutics.com |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc. Fundamentals Summary
| APLI fundamental statistics | |
|---|---|
| Market cap | CA$4.24m |
| Earnings (TTM) | -CA$3.58m |
| Revenue (TTM) | CA$484.11k |
8.8x
P/S Ratio-1.2x
P/E RatioIs APLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLI income statement (TTM) | |
|---|---|
| Revenue | CA$484.11k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$484.11k |
| Other Expenses | CA$4.07m |
| Earnings | -CA$3.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 100.00% |
| Net Profit Margin | -740.37% |
| Debt/Equity Ratio | -79.5% |
How did APLI perform over the long term?
See historical performance and comparison